Health ministry denies claims of tension between Mkhize and Ramaphosa over vaccine procurement

0:00
play article
Subscribers can listen to this article
President Cyril Ramaphosa together with Deputy President David Mabuza and Health Minister Dr Zweli Mkhize. (GCIS)
President Cyril Ramaphosa together with Deputy President David Mabuza and Health Minister Dr Zweli Mkhize. (GCIS)
  • The health ministry has denied claims in a Sunday report that there was tension between President Cyril Ramaphosa and Health Minister Zweli Mkhize over the acquisition of Covid-19 vaccines.
  • The article claims Mkhize preferred Russia's Sputnik V vaccine while Ramaphosa was in favour of Johnson & Johnson.
  • The health ministry has also denied claims that there was a bias towards Johnson & Johnson vaccines because they are manufactured by Aspen.

As South Africans still await word on the arrival of a new batch of vaccines from Johnson & Johnson, promised for this week, the Department of Health issued a four-page statement in which it denied that there was tension between the responsible political principals.

"The working relationship between President Cyril Ramaphosa, Deputy President David Mabuza, Health Minister Dr Zweli Mkhize, Cabinet and the National Coronavirus Command Council, has been one of support, value and efficiency," healthy ministry spokesperson Lwazi Manzi, said in a statement on Tuesday morning.

READ | SONA 2021: Ramaphosa thin on vaccine details, heavy on business

The statement was issued in reaction to a story in the Sunday Independent over the weekend.

She said:

The inference that there was a "tussle" between President Ramaphosa and Minister Mkhize is wholly untrue and is refuted entirely. So too are the comments made by shadowy unnamed sources quoted in the article who pass fallacious remarks about the president, the health minister and the government's Covid-19 vaccine acquisition strategy.

The article claimed Mkhize preferred Russia's Sputnik V vaccine and that Ramaphosa, supported by some members of the Ministerial Advisory Committee, was in favour of the Johnson & Johnson vaccine.

It also quoted a "bureaucrat" saying that Mkhize was unhappy that Mabuza, instead of himself, was appointed to lead the inter-ministerial committee to oversee the vaccine rollout, and that his views were disregarded.

CYRIL RAMAPHOSA | Let's get our economy back on its feet again

According to the article, Ramaphosa preferred the Johnson & Johnson vaccine because South African pharmaceutical company, Aspen, donated to his campaign to become president in 2017.

'Time has come'

CEO Stavros Nicolaou, however, denied this and told the publication: "Aspen is one of seven contract manufacturers that J&J have commissioned around the world to manufacture their candidate Covid vaccine. Aspen's intended role is purely that of a contract manufacturer and it does not tender, distribute, contract, sell or commercialise the vaccine to either the private or public sectors in SA or elsewhere. Aspen is neither an agent nor distributor of J&J."

Manzi echoed this statement by using some phrases word for word, and added that "no orders for vaccines will be placed with Aspen", but it's being negotiated directly with Johnson & Johnson.

She added:

While Aspen was contracted to supply Johnson & Johnson's needs, it does not have a direct contract with South Africa's government. It must be made obvious to all that the role of Aspen in vaccine production is a huge value-addition to our country’s ability to build future capacity in vaccine manufacturing – an idea whose time has now come.

Manzi also claimed in the statement that neither Ramaphosa nor Mkhize were involved in "the direct procurement of Covid-19 vaccinations, and therefore do not have individual 'preferences' for which vaccines should be purchased".

Seized with the matter

Ramaphosa, however, previously said he spoke directly to heads of state about South Africa's vaccine procurement, including Indian Prime Minister Narendra Modi, ahead of South Africa's procurement of 1.5 million doses of the AstraZeneca vaccine from the Serum Institute of India.

ALSO READ | Ramaphosa urges that time has come to shift gear from Covid relief to economic recovery

Manzi said:

Those responsible for this role are officials from the national Department of Health and National Treasury. South Africa’s vaccine acquisition strategy is derived from science, with the advice of leading experts within the Department of Health and those appointed to Ministerial Advisory Committees. The choice of which vaccines to procure is primarily guided by scientific findings and recommendations.

On Sunday, following an ANC national executive committee meeting, Ramaphosa also announced that South Africa was negotiating with Russia for its vaccine, but Manzi noted that "there are concerns that its Ad5 component (an adenovirus vector) has been flagged for further investigation relating to its effects on those living in a community with high HIV prevalence because of previous research".

Scientists are currently seized with detailed analyses of this matter.


Do you want to know more about this topic? Sign up for one of News24's 33 newsletters to receive the information you want in your inbox. Special newsletters are available to subscribers.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
When a Covid-19 vaccine for under 16's becomes available, will you be taking your children to get it?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, immediately!
37% - 2443 votes
I'll wait to see how others respond
26% - 1749 votes
No, I don't think they need it
37% - 2434 votes
Vote
ZAR/USD
15.09
(-0.16)
ZAR/GBP
21.02
(-0.23)
ZAR/EUR
18.22
(-0.19)
ZAR/AUD
11.62
(-0.25)
ZAR/JPY
0.14
(-0.54)
Gold
1734.50
(+0.02)
Silver
26.67
(+0.05)
Platinum
1186.51
(+0.42)
Brent Crude
64.40
(-2.56)
Palladium
2310.00
(+0.58)
All Share
66138.05
(-1.99)
Top 40
60754.30
(-2.11)
Financial 15
12200.05
(-1.09)
Industrial 25
86144.34
(-0.81)
Resource 10
67459.85
(-4.14)
All JSE data delayed by at least 15 minutes morningstar logo